HomeBUSINESS
BUSINESS

Keytruda-Chemo Combo Filed for NSCLC without PD-L1 Cutoff
(May.1.2018)

The Japan arm of US Merck on April 27 filed for approval of its anti-PD-1 antibody Keytruda (pembrolizumab) in combination with chemotherapy for the frontline treatment of non-small cell lung cancer (NSCLC) without PD-L1 expression cutoff ...
(LOG IN FOR FULL STORY)